Key result
The MITRIS RESILIA mitral valve was successfully implanted in a 20-year-old female, demonstrating good post-operative function with no perivalvular leak and an unobstructed left ventricular outflow tract.
Case Report (n=1)
No
The MITRIS RESILIA bioprosthetic valve was successfully implanted, offering a novel option for mitral valve replacement in patients at risk of left ventricular outflow tract obstruction.
Answers are grounded in this paper and cite their sources.
Supports feasibility in young patients at LVOTO risk; leaves open durability and broader applicability.
We report the first successful implantation in the United States of a novel mitral valve (MITRIS RESILIA by Edwards Lifesciences) in a patient with history of mitral valve replacement at a young age. This new bioprosthetic valve offers a unique profile and innovative option for mitral valve replacement in patients who are at risk of left ventricular outflow tract obstruction.
No takes yet. Share an insight, caveat, or question.
Heye et al. (2022) conducted a case report in Mitral valve stenosis (n=1). MITRIS RESILIA mitral valve was evaluated on Successful implantation and post-operative valve function. The MITRIS RESILIA mitral valve was successfully implanted in a 20-year-old female, demonstrating good post-operative function with no perivalvular leak and an unobstructed left ventricular outflow tract.
Synapse has enriched 10 related papers. Consider them for comparative context: